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Abstract
Introduction: Mutation, amplification or dysregulation of the EGFR family leads to uncontrolled division and 
predisposes to cancer. Inhibiting the EGFR represents a form of targeted cancer therapy.
Case report: We report the case of 79 year old gentlemen with a history of skin cancer involving the left ear who had 
radiation and surgical excision. He had presented with recurrent lymph node in the left upper neck. We treated him 
with radiation therapy concurrently with Cetuximab. He developed a skin rash over the face and neck area two weeks 
after starting Cetuximab, which however spared the previously irradiated area.
Conclusion: The etiology underlying the sparing of the previously irradiated skin maybe due to either decrease in the 
population of EGFR expressing cells or decrease in the EGFR expression.
We raised the question that "Is it justifiable to use EGFR inhibitors for patients having recurrence in the previously 
irradiated field?" We may need further research to answer this question which may guide the physicians in choosing 
appropriate drug in this scenario.
Introduction
The ErbB or epidermal growth factor family is a family of
four structurally related, EGFR/ErbB1/HER1, ErbB2/neu/
HER2, ErbB3/HER3, and ErbB4/HER4. ErbB receptors
are comprised of an extracellular region or ectodomain, a
single transmembrane spanning region, and a cytoplas-
mic tyrosine kinase domain [1]. Epidermal growth factor
receptors (EGFR), upon activation by their respective
ligands, undergo a transformation from the inactive
monomeric form into an active homo or hetero-dimer.
This process stimulates its intrinsic intracellular protein-
tyrosine kinase activity [2].
Mutation, amplification, or dysregulation of the EGFR
family leads to uncontrolled division and predisposes the
individual to cancer development [3]. EGFR over-expres-
sion has also been correlated with disease progression,
poorer prognosis, and reduced sensitivity to chemother-
apy [4]. Inhibiting the EGFR - by directly blocking the
extracellular EGFR receptor domain with monoclonal
antibodies or by inhibiting the intra-cytoplasmic ATP
binding site with tyrosine kinase inhibitors (TKI's) - rep-
resents an accepted form of targeted cancer therapy[5].
Data from a large, randomized, phase III study of
patients with locally advanced squamous cell carcinoma
(SCC) of the head and neck suggests that blockade of the
EGFR pathway may improve the efficacy of radiation
therapy and improve survival [6]. In this study, EGFR
blockade was achieved with the monoclonal antibody
Cetuximab (Erbitux). There was no significant difference
in the rate of mucositis seen in either treatment arm, but
there was a higher incidence of grade 3/4 skin reactions
when the combined high dose radiation/Cetuximab was
employed. Nonetheless, the addition of Cetuximab was
associated with a significant improvement in overall sur-
vival (median 54 v 28 months; p = 0.02) compared to radi-
ation alone.
EGFR inhibition, whether with antibodies or TKI,
causes a cutaneous rash in almost 70% of patients receiv-
ing such therapy; generally it involves the face, neck, and
upper chest. The severity of rash has been correlated to
progression-free survival in cetuximab and erlotinib
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treatment and it has been suggested that the rash may be
a surrogate marker for efficacy [7]. The severity of the
rash peaks during the first 1-2 weeks of therapy, stabiliz-
ing in intensity thereafter [8], and it characteristically
develops in the following phases:
(a). Sensory disturbance with erythema and edema
(week 0-1)
(b). Papulopustular eruption (weeks 1-3)
(c). Crusting (weeks 3-5)
(d). Ending with erythema to telangiectasias (weeks 5-
8).
Even if it has resolved or greatly diminished during the
second month (weeks 4-6), the erythema and dry skin
remain in areas previously dominated by the papulopus-
tular eruption [9].
Here, we report a case of lack of Cetuximab-induced
skin rash in an area that had previously been irradiated
for SCC and present a brief review of the literature.
Case Report
A 78-year-old Caucasian male was diagnosed with a well
differentiated squamous cell carcinoma (SCC) of the skin
over the left ear. This was initially excised and treated
with adjuvant radiation treatment using 12 MeV elec-
trons between January and March 2008. An initial dose of
50 Gy was delivered to the external ear and the adjacent
lymph node region, followed by a 10 Gy boost to the
expanded GTV, and completed with an additional 6 Gy to
a residual nodular area on the posterior surface of the ear.
He later underwent excision of this nodular area with
placement of a skin graft derived from the left supra-
clavicular area.
In Dec 2008, seven months following completion of his
definitive therapy, the patient presented with a palpable
swelling in the left upper neck which had been gradually
increasing in size for two months (this was in the region
that had received 5,000 cGy during the previous course of
radiation). A fine needle aspiration biopsy revealed cells
consistent with recurrent SCC. Computed tomography
(CT) performed for staging showed a solitary 3.1 cm
enhancing mass in the left post-auricular region, with
infiltration of the left sternocleidomastoid muscle. No
other disease was apparent.
Following evaluations in both medical and radiation
oncology, the clinical consensus was to proceed with re-
irradiation with concurrent Cetuximab. He was therefore
treated with 6 MV photons using an intensity modulated
radiotherapy (IMRT) technique. Cetuximab was adminis-
tered in standard fashion concurrently with his radiation
therapy.
Approximately two weeks into his treatment, he devel-
oped the anticipated papulo-pustular skin lesions on his
neck. Surprisingly, however, there was no such skin reac-
tion in the previously irradiated field which shared con-
siderable overlap with the current re-irradiation field
(Fig-1 & Fig-2). During follow up appointments the
Cetuximab-induced rash seen elsewhere gradually
resolved but slight erythema persisted in the area previ-
ously covered by the rash.
In May 2009, approximately five months after his radia-
tion treatment, he was found to have a second recurrence
in the left neck, corresponding to a level Va lymph node,
and he underwent resection of the involved node. In
December 2009, he was diagnosed with dermal metasta-
sis involving the left neck, recurrent lymph node involve-
ment corresponding to the area of previous surgical
resection in neck, as well as the development of a new
node in the left parotid gland. At this point, he was
deemed unresectable and was offered palliative chemo-
therapy.
Discussion
EGFR is expressed in undifferentiated, proliferating kera-
tinocytes in the basal and suprabasal layers of the epider-
mis, skin fibroblasts, and in the outer root sheath of the
hair follicles [10]. EGFR plays a crucial role in the normal
maturation and development of epidermis. Activation of
EGFR in the skin causes stimulation of epidermal growth
and inhibition of differentiation [11]. Reduction and
impairment of functional stem cells, endothelial cell
changes, and inflammation constitute the main patho-
physiology underlying acute radiation injury [12],
whereas microvascular injury from endothelial cell dam-
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age and fibrosis, both mediated by TGF-β, is intricately
involved in the chronic radiation dermatitis [13]. Cetux-
imab is a monoclonal antibody inhibitor of the EGFR that
has been shown in a large, randomized phase III study to
improve survival when delivered concurrently with radia-
tion therapy for advanced head and neck SCC. Its admin-
istration is typically associated with a skin rash.
Our review of the literature revealed only a single case
series report documenting the lack of a Cetuximab-
induced skin rash in the previously radiated field [14]. In
this report, Bossi et al identified six cases with sparing of
skin toxicity induced by cetuximab in previously irradi-
ated areas. The interval between previous radiation and
cetuximab therapy ranged from 3 months to 70 months
(median 15.5 months). They reviewed the possibility of
microvascular injury that may have impeded delivery of
the small molecules to their targets.
Despite the single case series report regarding Cetux-
imab, we identified three case reports documenting spar-
ing of the skin in the previous radiation field in patients
treated with erlotinib, a small molecule inhibitor of
tyrosine kinase. Again, the interval between the previous
radiation treatment and administration erlotinib varied, 9
months after prior treatment with 64 Gy [15], 4 months
after 39 Gy [16], and 2 months after 45 Gy [17]. Yalcin et
al also biopsied the previously irradiated skin that was
devoid of the skin rash and found normal EGFR expres-
sion but a conspicuous absence of follicular structures.
They hypothesized that the lack of follicular structure in
the irradiated skin biopsy was the reason underlying the
lack of a skin rash.
Two other case reports have demonstrated a temporal
dependence between the timing of erlotinib therapy and
the radiation treatment. In a report by Lacouture et al,
erlotinib given immediately after radiation treatment
resulted in a severe, confluent skin rash over the irradi-
ated area compared to other parts of skin involved with
skin rash. It was thought that this phenomenon was sec-
ondary to the radio sensitizing properties of the EGFR
inhibitors [18]. Gerber et al treated a 55 year-old woman
with metastatic NSCLC who developed a characteristic
papulopustular rash on the face, trunk and upper extrem-
ities in response to erlotinib therapy. The rash, however,
spared a rectangular area over the lower vertebral col-
umn, extending from T8 through T12, where she had
received radiation therapy two months previously for
osseous metastases. Interestingly, however, two months
after erlotinib therapy was initiated and 4 months after
radiation treatment was completed, she proceeded to
develop the characteristic skin rash in the initially spared
area, suggesting a radiation recall type phenomenon [19].
The etiology underlying the sparing of the previously
irradiated skin from the expected cetuximab-induced
skin rash in our patient is uncertain. In addition to the
lack of follicular structures [17], another possible mecha-
nism is the diminished number of EGFR expressing cells
after radiation. Alternative hypotheses include stunted
receptor function, diminished receptor sensitivity, or
impaired transmembrane signaling.
In addition, because the severity of the skin rash has
been associated with treatment efficacy [7], one should
consider the possibility that the therapy may not be as
beneficial in the absence of a skin reaction. Our patient
had a recurrence in a previously irradiated area where
skin sparing was noted during his re-irradiation. Despite
the re-irradiation and subsequent surgical resection he
proceeded to develop a recurrence in the same area. He is
now deemed unresectable and is undergoing palliative
chemotherapy. Although we should be cautious in the use
of concurrent epidermal growth factor inhibitors in the
radiation treatment of recurrences in previously irradi-
ated areas, further research at the molecular level is nec-
essary to obtain a better understanding of the etiology
and variability of the skin toxicity induced in patients
undergoing combined therapy.
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